| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 3.04 +3.29% on 03/28/25 |
Period Open: 3.58
| 3.75 -16.27% on 03/06/25 | -0.44 (-12.29%) since 02/28/25 |
| 3-Month | 2.69 +16.73% on 02/11/25 |
Period Open: 3.08
| 4.06 -22.66% on 01/07/25 | +0.06 (+1.95%) since 12/27/24 |
| 52-Week | 2.22 +41.12% on 09/06/24 |
Period Open: 5.30
| 6.05 -48.14% on 04/09/24 | -2.16 (-40.75%) since 03/28/24 |
Puma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted...
Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational pipeline candidates, VIR-5818 and VIR-5500, for the treatment of various solid tumors.While...
Shares of CorMedix CRMD rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures.CorMedix’s Preliminary Sales Figures Beat EstimatesCorMedix reported...
For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...
Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks Rank #2 (Buy) company boasts a pipeline of differentiated therapies across a...
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 6:NRx Pharmaceuticals, Inc. NRXP: This bio-pharmaceutical company has a Zacks Rank #1 and...
Here are three stocks with buy rank and strong value characteristics for investors to consider today, January 6:Ashford Hospitality Trust, Inc. AHT: This real estate investment trust carries a Zacks Rank...
Shares of Puma Biotechnology, Inc. PBYI have rallied 24% in the past three months against the industry’s decline of 9.7%.The company’s sole marketed product, Nerlynx (neratinib), is approved for treating...
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 24:Puma Biotechnology, Inc. PBYI: This biopharmaceutical company has a Zacks Rank #1 and...
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 24:Puma Biotechnology, Inc. PBYI: This biopharmaceutical company carries a Zacks Rank #1,...
Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The...
Puma Biotechnology, Inc. PBYI reported third-quarter 2024 adjusted earnings of 45 cents per share, which beat the Zacks Consensus Estimate of 35 cents. In the year-ago quarter, the company had reported...
A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...
A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...
A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Unless otherwise stated, all comparisons are for the first...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023...
A significant medical breakthrough is sorely needed in the fight against breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 8, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December...
| Symbol | %Holdings | 3M %Chg |
|---|---|---|
| PBYI | +1.95% | |
| Puma Biotechnology | ||
| SQLV | 0.26% | -11.19% |
| Royce Quant Small-Cap Quality Value ETF | ||
| IWC | 0.04% | -14.50% |
| Micro-Cap Ishares ETF | ||
| FLQS | 0.02% | -6.38% |
| Franklin Liberty U.S. Small Cap Equity ETF | ||
| GSSC | 0.02% | -8.82% |
| GS Activebeta U.S. Small Cap Equity ETF | ||
| IWM | 0.01% | -9.87% |
| Russell 2000 Ishares ETF | ||
Please check your inbox for a link to activate your My Barchart Account.
If you do not receive the email within a few minutes check your spam folder or contact our support team for assistance.
